vs
艾伯维（ABBV）与Aveanna Healthcare Holdings, Inc.（AVAH）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Aveanna Healthcare Holdings, Inc.的26.7倍（$16.6B vs $621.9M）。艾伯维净利率更高（10.9% vs 2.3%，领先8.7%）。Aveanna Healthcare Holdings, Inc.同比增速更快（22.2% vs 10.0%）。过去两年艾伯维的营收复合增速更高（16.2% vs 14.0%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
Aveanna Healthcare Holdings, Inc.是美国领先的家庭及社区医疗服务提供商，核心业务覆盖儿科家庭护理、成人个人照护、临终关怀、输液治疗等领域，通过覆盖全美的本地护理中心网络为各地患者提供服务，服务对象涵盖公共及私人付费群体。
ABBV vs AVAH — 直观对比
营收规模更大
ABBV
是对方的26.7倍
$621.9M
营收增速更快
AVAH
高出12.1%
10.0%
净利率更高
ABBV
高出8.7%
2.3%
两年增速更快
ABBV
近两年复合增速
14.0%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $621.9M |
| 净利润 | $1.8B | $14.1M |
| 毛利率 | 72.6% | 32.6% |
| 营业利润率 | 27.3% | 8.6% |
| 净利率 | 10.9% | 2.3% |
| 营收同比 | 10.0% | 22.2% |
| 净利润同比 | 8354.5% | 132.8% |
| 每股收益（稀释后） | $1.02 | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVAVAH
| Q4 25 | $16.6B | — | ||
| Q3 25 | $15.8B | $621.9M | ||
| Q2 25 | $15.4B | $589.6M | ||
| Q1 25 | $13.3B | $559.2M | ||
| Q4 24 | $15.1B | $519.9M | ||
| Q3 24 | $14.5B | $509.0M | ||
| Q2 24 | $14.5B | $505.0M | ||
| Q1 24 | $12.3B | $490.7M |
净利润ABBVAVAH
| Q4 25 | $1.8B | — | ||
| Q3 25 | $186.0M | $14.1M | ||
| Q2 25 | $938.0M | $27.0M | ||
| Q1 25 | $1.3B | $5.2M | ||
| Q4 24 | $-22.0M | $29.2M | ||
| Q3 24 | $1.6B | $-42.8M | ||
| Q2 24 | $1.4B | $13.9M | ||
| Q1 24 | $1.4B | $-11.2M |
毛利率ABBVAVAH
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | 32.6% | ||
| Q2 25 | 71.8% | 35.8% | ||
| Q1 25 | 70.0% | 32.8% | ||
| Q4 24 | 70.9% | 33.0% | ||
| Q3 24 | 70.9% | 31.4% | ||
| Q2 24 | 70.9% | 31.3% | ||
| Q1 24 | 66.7% | 29.7% |
营业利润率ABBVAVAH
| Q4 25 | 27.3% | — | ||
| Q3 25 | 12.1% | 8.6% | ||
| Q2 25 | 31.7% | 13.6% | ||
| Q1 25 | 28.0% | 9.3% | ||
| Q4 24 | -9.9% | 8.8% | ||
| Q3 24 | 26.5% | 6.7% | ||
| Q2 24 | 27.6% | 7.4% | ||
| Q1 24 | 22.7% | 4.7% |
净利率ABBVAVAH
| Q4 25 | 10.9% | — | ||
| Q3 25 | 1.2% | 2.3% | ||
| Q2 25 | 6.1% | 4.6% | ||
| Q1 25 | 9.6% | 0.9% | ||
| Q4 24 | -0.1% | 5.6% | ||
| Q3 24 | 10.8% | -8.4% | ||
| Q2 24 | 9.5% | 2.8% | ||
| Q1 24 | 11.1% | -2.3% |
每股收益（稀释后）ABBVAVAH
| Q4 25 | $1.02 | — | ||
| Q3 25 | $0.10 | $0.06 | ||
| Q2 25 | $0.52 | $0.13 | ||
| Q1 25 | $0.72 | $0.03 | ||
| Q4 24 | $-0.03 | $0.15 | ||
| Q3 24 | $0.88 | $-0.22 | ||
| Q2 24 | $0.77 | $0.07 | ||
| Q1 24 | $0.77 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $145.9M |
| 总债务越低越好 | $58.9B | $1.3B |
| 股东权益账面价值 | $-3.3B | $9.2M |
| 总资产 | $134.0B | $1.8B |
| 负债/权益比越低杠杆越低 | — | 141.83× |
8季度趋势，按日历期对齐
现金及短期投资ABBVAVAH
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.7B | $145.9M | ||
| Q2 25 | $6.5B | $100.7M | ||
| Q1 25 | $5.2B | $71.5M | ||
| Q4 24 | $5.6B | $84.3M | ||
| Q3 24 | $7.3B | $78.5M | ||
| Q2 24 | $13.2B | $47.7M | ||
| Q1 24 | $18.1B | $42.6M |
总债务ABBVAVAH
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | $1.3B | ||
| Q2 25 | $63.0B | $1.3B | ||
| Q1 25 | $64.5B | $1.3B | ||
| Q4 24 | $60.3B | $1.3B | ||
| Q3 24 | $58.5B | $1.3B | ||
| Q2 24 | $58.0B | $1.3B | ||
| Q1 24 | $63.8B | $1.3B |
股东权益ABBVAVAH
| Q4 25 | $-3.3B | — | ||
| Q3 25 | $-2.6B | $9.2M | ||
| Q2 25 | $-183.0M | $-12.0M | ||
| Q1 25 | $1.4B | $-100.1M | ||
| Q4 24 | $3.3B | $-123.6M | ||
| Q3 24 | $6.0B | $-156.4M | ||
| Q2 24 | $6.8B | $-119.0M | ||
| Q1 24 | $8.0B | $-136.3M |
总资产ABBVAVAH
| Q4 25 | $134.0B | — | ||
| Q3 25 | $133.9B | $1.8B | ||
| Q2 25 | $137.2B | $1.8B | ||
| Q1 25 | $136.2B | $1.7B | ||
| Q4 24 | $135.2B | $1.7B | ||
| Q3 24 | $143.4B | $1.6B | ||
| Q2 24 | $141.9B | $1.7B | ||
| Q1 24 | $148.9B | $1.6B |
负债/权益比ABBVAVAH
| Q4 25 | — | — | ||
| Q3 25 | — | 141.83× | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $33.2M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 2.0% | — |
| 现金转化率经营现金流/净利润 | 2.87× | 2.36× |
| 过去12个月自由现金流最近4个季度 | $17.8B | — |
8季度趋势，按日历期对齐
经营现金流ABBVAVAH
| Q4 25 | $5.2B | — | ||
| Q3 25 | $7.0B | $33.2M | ||
| Q2 25 | $5.2B | $51.6M | ||
| Q1 25 | $1.6B | $-8.6M | ||
| Q4 24 | $7.0B | $13.4M | ||
| Q3 24 | $5.4B | $29.4M | ||
| Q2 24 | $2.3B | $1.8M | ||
| Q1 24 | $4.0B | $-12.0M |
自由现金流ABBVAVAH
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $3.8B | — |
自由现金流率ABBVAVAH
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | 31.3% | — |
资本支出强度ABBVAVAH
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.6% | — |
现金转化率ABBVAVAH
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | 2.36× | ||
| Q2 25 | 5.49× | 1.91× | ||
| Q1 25 | 1.27× | -1.66× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | 0.13× | ||
| Q1 24 | 2.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
AVAH
| Private Duty Services | $514.4M | 83% |
| Home Health And Hospice | $62.4M | 10% |
| Medical Solutions | $45.1M | 7% |
